^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) + Sarclisa (isatuximab-irfc) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
301 Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)
Published date:
11/02/2023
Excerpt:
We aimed to analyze the efficacy of isatuximab (anti-CD38 monoclonal antibody) and cemiplimab (anti-PD1 monoclonal antibody) in patients with R/R ENKTL….The response rate was determined by the best response during treatment. As 16 patients achieved CR, the CR rate was 43% (16/37). Thus, the primary end point was met in the study. The ORR was 65% (24/37) consisting of 16 CR and 8 PR....The combination of isatuximab with cemiplimab showed durable antitumor activity and manageable safety profiles in R/R ENKTL. Especially, patients with PD-L1 expression showed better outcomes than patients with low PD-L1 expression.
